BoB Jury

BoB Jury

The BOB jury is made up of distinguished experts from the worlds of science, industry and finance and will be responsible for selecting the three best business plans as well as the winner of the LISAvienna Medtech award in phase 2. The jury also provides extensive feedback to all presenting teams. All jury members have signed a strict confidentiality Agreement.​

Klaus Binder, Binder Associates GmbH 

Dr. Klaus Binder combines more than 25 years of experience in the international Life Science and Health Care Industry. His focus is pharmaceutical development, corporate development and M&A. In addition to his consulting tasks, Dr. Binder helds several board and advisory seets in Europe and the USA. Since 2000 Dr. Binder consults pharmaceutical- and biotechnology companies with respect to product- and corporate development. He is founder and managing director of BINDER ASSOCIATES GmbH and has supported a number of companies from early stage to exit. ​

Before starting his own firm, Dr. Binder was responsible for different functions in international Business Development and Strategic Marketing of Boehringer Ingelheim. In his last position he was Head of Corporate Business Development & Marketing of the Biopharmaceutical Contract Manufacturing Business of Boehringer Ingelheim GmbH. Before that Dr. Binder did spend 6 years in pharmaceutical R&D heading the Coagulation Research of Boehringer Ingelheim KG. ​

Arnold Fehér, Founder and Managing Partner, Convincive Consulting

Dr. Arnold Fehér is founder and managing partner at Convincive Consulting. ​

Convincive provides strategy and business development advisory for biotech / life sciences companies, scientists and innovators with ideas to be commercialized, R&D or TTO institutions (universities, centers of excellence, hospitals, bioincubators, science parks etc.), sector capital investors, authorities and policy makers in Hungary and Europe. ​

Between 2001 and 2004, Dr. Fehér was director of business development at Solvo Biotechnology, a Hungarian biotech company commercialising products and technologies for the pharmaceutical industry world wide. Before, Dr. Fehér gained three years experience in strategy consulting at The Boston Consulting Group’s Budapest office, developing strategies for pharmaceuticals and other technology and services sectors world wide. Previously, Dr. Fehér spent three years in different sales positions at Abbott Diagnostics and two Hungarian healthcare SMEs. ​

Dr. Fehér is an M.D. and also holds an M.Sc. in Business Administration specialized in finance and entrepreneurship. Dr. Fehér leads the Strategic Committee of the Hungarian Biotechnology Association since 2008.​

Michaela Fritz, Vice-Rector for Research and Innovation, Medical University Vienna​

Since October 2015 DI Dr. Michaela Fritz is vice rector for research and innovation at the Medical University of Vienna. MedUni Vienna is not only the largest medical organisation in Austria, it is also one of the most important top-level research institutions in Europe and provides Europe's largest hospital, the AKH in Vienna, with all of its medical staff.​

DI Dr. Michaela Fritz was Head of the Health & Environment Department of the AIT Austrian Institute of Technology. Research at the Department is aimed at developing innovative technologies to improve human health and at investigating natural resources and their interactions to safeguard ecological sustainability. Until 2016 she was president of the association AAL Austria – innovation platform for intelligent assistance in daily life.​

From 2005 to 2010 Michaela Fritz worked for Austria Wirtschaftsservice GmbH, where she was responsible for the LISA (Life Science Austria) programme and was actively involved in strategic planning, supporting start-ups and promoting Austria as a key life sciences location. During that time she also held the position of Managing Director of the Vienna cluster initiative LISA VR (Life Sciences Austria Vienna Region). Prior to that she spent several years in Munich working as a Senior Manager in business development for Infineon Technologies AG Bioscience. Before moving to industry, Michaela Fritz worked as a research assistant at ETH Zurich. After graduating in materials science (ETH Zurich) she completed her post-doctoral studies at the University of California, Berkeley.​

Regina Hodits, Wellington Partners

Regina is a General Partner at Wellington Partners and represents the Wellington funds on the Boards of Endostim, G-Therapeutics, Themis, Rigontec, Middle Peak Medical, Ayoxxa and Atopix. She was a founding investor in Sapiens, which was sold to Medtronic, and an external director at GSK's Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.

Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm, until January 2010. She was the founding investor in Bicycle Therapeutics, F-star, and Jenavalve. Regina served on several Boards, including the Board of U3 Pharma, which was acquired by Daiichi Sankyo, Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), Egalet (NASDAQ: EGLT), and Novamed, which was acquired by SciClone (NASDAQ SCLN) in 2010.

Before, Regina worked for Apax Partners and was closely involved in investments such as Genmab and Silence Therapeutics. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey from 1997 to 2000. In the 90s, Regina gained initial insights into the fast-growing biotech sector as post-doctoral researcher at the MRC Cambridge UK, where she collaborated with emerging UK biotech companies. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.​

Marion Jung, CEO, ChromoTek GmbH​

Marion Jung joined ChromoTek as their CEO in 2011. ChromoTek is a fast growing international life science company located in Martinsried, Germany’s leading biotech cluster. ChromoTek’s proprietary nanobody-based tools and reagents set new benchmarks for proteomic and cellular research.​

Before ChromoTek, she worked 13 years for a leading European venture capital company. Her focus was early- stage investments in biotechnology, pharmaceutical and medical device companies. With her broad international network, Marion supported her portfolio companies to achieve their value-creating milestones through several financing rounds and Exit.​

Marion studied molecular biology and biochemistry at the Ludwig-Maximilians-University in Munich. She earned a PhD under the supervision of Prof. Dr. Svante Pääbo and authored several research articles.​

Jürgen Kosch, CEO MIG Fonds​

Mr. Jürgen Kosch has been an active entrepreneur in the IT business for more than 25 years. He founded several companies and established them on the international market. Mr. Kosch has in depth experience as a business angel and business-coach. Starting from 2003, he has been a consultant to  Venture Capital funds. As member of the MIG executive board, Jürgen Kosch is responsible for the technological assessment and development of the investment pipeline.  ​

MIG Verwaltungs AG (MIG) provides management services to the MIG funds, which are public Venture Capital funds. The MIG funds have a total volume of more than 900 million Euros and provide Venture Capital to young, non-listed companies located in German-speaking Europe. The investment strategy and assistance to the portfolio companies is greatly determined by the entrepreneurial experience of the MIG team. ​

Eva Prieschl-Grassauer, Chief Scientific Officer, Marinomed​

Dr. Prieschl-Grassauer has more than ten years of experience working in pharmaceutical drug development. She is founder and owner of Marinomed, a biopharmaceutical company discovering and developing innovative naturally-derived immunological and antiviral treatments. Before Marinomed, she was head of the allergy program at Novartis in Vienna. In this position she also discovered the mechanism of action of FTY720 (Fingolimod), Novartis´ novel immunomodulatory drug against multiple sclerosis. Following that, she supervised the clinical development of an innovative cancer therapy drug that was in clinical phase III at that time.​

Dr. Prieschl-Grassauer has published more than 30 articles in high ranking peer-reviewed journals in the field of immunology, molecular biology and medicinal chemistry. ​

Joachim Rothe, Managing Partner, LSP​

Joachim (JR) Rothe, PhD, joined LSP in 2002 and is currently a Managing Partner and co-owner of the firm. His prime focus and responsibility within LSP is to invest in unlisted securities and the general management of the firm. Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Hoffmann-La Roche in Switzerland. Joachim brings a strong scientific background and in-depth knowledge of the pharmaceutical and biotechnology industries to the LSP team. He has been appointed a Director of a large number of companies, all of which he has helped to grow by leveraging his scientific expertise, pharmaceutical experience and global networks. Among others, Joachim is currently a Director at Atlas Genetics, a UK diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases.​

Joachim obtained a Master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. He has authored numerous articles in leading scientific publications, including Nature.​

Robert Schier, Managing Director, Bridging Minds​

Dr. Robert Schier is founder and managing director of Bridging Minds Sàrl, a company providing management services for life science investors and companies.  Since 2009 he had several strategic and C-level operational engagements and in 2011 he became a start-up coach for the Swiss Commission for Technology and Innovation. Between 2010 and 2016 he held also the position of venture partner in the life sciences team of the venture capital firm Seventure Partners. Prior to Bridging Minds, Robert was partner and investment director at Inventages Venture Capital. Before joining Inventages, Robert held several R&D and business positions in biotech companies in the Munich area.​

Robert holds academic degrees in pharmacy, applied microbiology and cell biology, as well as in business administration. He is co-author of several patents and scientific publication, and received the Keystone Award for Excellence in Research.​

Angelika Weinländer-Mölders, IMCD Deutschland GmbH​

Dr. Angelika Weinländer-Mölders has more than 15 years of experience in the medical equipment business with a generalist background and a sales and marketing focus. From 2009  to 2015 she was responsible as chief executive officer for Caesar & Loretz, a company in the pharmaceutical industry. Before Dr. Angelika Weinländer-Mölders was working for small, mid-sized and large companies in several positions as CEO, Business Unit Director or Commercial Director with a focus of establishing or re-structuring of internationally active business units.​

Dr. Angelika Weinländer-Mölders holds a Ph.D in Chemistry from the university Friderciana Karlsruhe.​